{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:55:42Z","timestamp":1791896142103,"version":"4.3.4"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04293\/2020"],"award-info":[{"award-number":["UIDB\/04293\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/QUI-COL\/2444\/2021"],"award-info":[{"award-number":["PTDC\/QUI-COL\/2444\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/147826\/2019"],"award-info":[{"award-number":["SFRH\/147826\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP50026\/2020"],"award-info":[{"award-number":["UIDP50026\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/50026\/2020"],"award-info":[{"award-number":["UIDB\/50026\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["952334"],"award-info":[{"award-number":["952334"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115258","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T06:20:01Z","timestamp":1691216401000},"page":"115258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Drug repurposing of dopaminergic drugs to inhibit ataxin-3 aggregation"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5933-9875","authenticated-orcid":false,"given":"Francisco","family":"Figueiredo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9185-8210","authenticated-orcid":false,"given":"Zsuzsa","family":"S\u00e1rk\u00e1ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8786-6680","authenticated-orcid":false,"given":"Daniela","family":"Vilasboas-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Maciel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Teixeira-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro M.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Macedo-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115258_bib1","series-title":"in: Polyglutamine Disorders","first-page":"233","article-title":"The neuropathology of spinocerebellar ataxia type 3\/Machado-Joseph disease","author":"Koeppen","year":"2018"},{"key":"10.1016\/j.biopha.2023.115258_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0896-6273(00)80943-5","article-title":"Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3","volume":"19","author":"Paulson","year":"1997","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2023.115258_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-012-1000-x","article-title":"Brain pathology of spinocerebellar ataxias","volume":"124","author":"Seidel","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.biopha.2023.115258_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/bpa.12412","article-title":"On the distribution of intranuclear and cytoplasmic aggregates in the brainstem of patients with spinocerebellar ataxia type 2 and 3: protein aggregation in the brainstem of SCA2 and SCA3 patients","volume":"27","author":"Seidel","year":"2017","journal-title":"Brain Pathol."},{"key":"10.1016\/j.biopha.2023.115258_bib5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ana.410410408","article-title":"Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain","volume":"41","author":"Paulson","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2023.115258_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12311-008-0013-4","article-title":"SCA3: Neurological features, pathogenesis and animal models","volume":"7","author":"Riess","year":"2008","journal-title":"Cerebellum"},{"key":"10.1016\/j.biopha.2023.115258_bib7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2990.2011.01220.x","article-title":"Cellular protein quality control and the evolution of aggregates in spinocerebellar ataxia type 3 (SCA3): aggregation and protein quality control in SCA3","volume":"38","author":"Seidel","year":"2012","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.biopha.2023.115258_bib8","series-title":"Polyglutamine disorders","first-page":"369","article-title":"Pharmacological therapies for Machado-Joseph disease","author":"Duarte-Silva","year":"2018"},{"key":"10.1016\/j.biopha.2023.115258_bib9","series-title":"Polyglutamine Disorders","first-page":"255","article-title":"Clinical features of Machado-Joseph Disease","author":"Mendon\u00e7a","year":"2018"},{"key":"10.1016\/j.biopha.2023.115258_bib10","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ana.410380422","article-title":"Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion","volume":"38","author":"Tuite","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2023.115258_bib11","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.12998\/wjcc.v9.i28.8552","article-title":"Spinocerebellar ataxia type 3 with dopamine-responsive dystonia: a case report","volume":"9","author":"Zhang","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.biopha.2023.115258_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pneurobio.2011.06.007","article-title":"Polyglutamine diseases: the special case of ataxin-3 and Machado\u2013Joseph disease","volume":"95","author":"Matos","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.biopha.2023.115258_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jsb.2017.09.006","article-title":"Polyglutamine expansion diseases: more than simple repeats","volume":"201","author":"Silva","year":"2018","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.biopha.2023.115258_bib14","series-title":"Polyglutamine Disorders","first-page":"275","article-title":"Polyglutamine-independent features in ataxin-3 aggregation and pathogenesis of Machado-Joseph disease","author":"Carvalho","year":"2018"},{"key":"10.1016\/j.biopha.2023.115258_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.621996","article-title":"Protein aggregation inhibitors as disease-modifying therapies for polyglutamine diseases","volume":"15","author":"Minakawa","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.biopha.2023.115258_bib16","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s13311-019-00798-1","article-title":"From pathogenesis to novel therapeutics for spinocerebellar ataxia type 3: evading potholes on the way to translation","volume":"16","author":"Da Silva","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.biopha.2023.115258_bib17","doi-asserted-by":"crossref","first-page":"18851","DOI":"10.1074\/jbc.M611914200","article-title":"Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3","volume":"282","author":"Haacke","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.115258_bib18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.omtn.2021.11.015","article-title":"Allele-specific targeting of mutant ataxin-3 by antisense oligonucleotides in SCA3-iPSC-derived neurons","volume":"27","author":"Hauser","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2023.115258_bib19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","article-title":"Evaluation of antisense oligonucleotides targeting ATXN3 in SCA3 mouse models","volume":"7","author":"Moore","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2023.115258_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003341","article-title":"Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease","volume":"3","author":"Alves","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.115258_bib21","doi-asserted-by":"crossref","first-page":"16888","DOI":"10.1074\/jbc.M601470200","article-title":"The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step","volume":"281","author":"Ellisdon","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.115258_bib22","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3390\/cells11121969","article-title":"A robust assay to monitor ataxin-3 amyloid fibril assembly","volume":"11","author":"Figueiredo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2023.115258_bib23","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jmb.2005.08.061","article-title":"Towards a structural understanding of the fibrillization pathway in Machado-Joseph\u2019s disease: trapping early oligomers of non-expanded ataxin-3","volume":"353","author":"Gales","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.biopha.2023.115258_bib24","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1074\/mcp.M114.044610","article-title":"Examination of ataxin-3 (atx-3) aggregation by structural mass spectrometry techniques: a rationale for expedited aggregation upon polyglutamine (polyQ) expansion","volume":"14","author":"Scarff","year":"2015","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.biopha.2023.115258_bib25","doi-asserted-by":"crossref","first-page":"14042","DOI":"10.1002\/anie.201707345","article-title":"Distribution of amyloid-like and oligomeric species from protein aggregation kinetics","volume":"56","author":"Silva","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biopha.2023.115258_bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/biom8040108","article-title":"Probing the occurrence of soluble oligomers through amyloid aggregation scaling laws","volume":"8","author":"Silva","year":"2018","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2023.115258_bib27","series-title":"Polyglutamine Disorders","first-page":"321","article-title":"Planning future clinical trials for Machado-Joseph disease","author":"Saute","year":"2018"},{"key":"10.1016\/j.biopha.2023.115258_bib28","doi-asserted-by":"crossref","first-page":"30585","DOI":"10.1074\/jbc.M112.375345","article-title":"A generic crystallization-like model that describes the kinetics of amyloid fibril formation","volume":"287","author":"Crespo","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.115258_bib29","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1093\/hmg\/ddr203","article-title":"Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways","volume":"20","author":"Teixeira-Castro","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biopha.2023.115258_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/genetics\/77.1.71","article-title":"The genetics of caenorhabditis elegans","volume":"77","author":"Brenner","year":"1974","journal-title":"Genetics"},{"key":"10.1016\/j.biopha.2023.115258_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000504","article-title":"Identification of potential therapeutic drugs for Huntington\u2019s disease using Caenorhabditis elegans","volume":"2","author":"Voisine","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.biopha.2023.115258_bib32","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1093\/brain\/awv262","article-title":"Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease","volume":"138","author":"Teixeira-Castro","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2023.115258_bib33","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1126\/science.1124514","article-title":"Progressive disruption of cellular protein folding in models of polyglutamine diseases","volume":"311","author":"Gidalevitz","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.115258_bib34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jneumeth.2006.11.015","article-title":"An automated tracking system for Caenorhabditis elegans locomotor behavior and circadian studies application","volume":"161","author":"Simonetta","year":"2007","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.biopha.2023.115258_bib35","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/asia.201801703","article-title":"Chemical kinetic strategies for high-throughput screening of protein aggregation modulators","volume":"14","author":"S\u00e1rk\u00e1ny","year":"2019","journal-title":"Chem. Asian J."},{"key":"10.1016\/j.biopha.2023.115258_bib36","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/ijms21020591","article-title":"Structural, molecular, and functional alterations of the blood-brain barrier during epileptogenesis and epilepsy: a cause, consequence, or both?","volume":"21","author":"L\u00f6scher","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115258_bib37","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1021\/acs.jmedchem.6b00666","article-title":"Development of blood\u2013brain barrier permeable nitrocatechol-based catechol O -methyltransferase inhibitors with reduced potential for hepatotoxicity","volume":"59","author":"Silva","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2023.115258_bib38","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant\u2019Anna","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.115258_bib39","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1021\/acs.jmedchem.9b01338","article-title":"Development of novel N -hydroxypyridone derivatives as potential anti-ischemic stroke agents","volume":"63","author":"Hu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2023.115258_bib40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2023.115258_bib41","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3390\/ph15050512","article-title":"Using a Caenorhabditis elegans Parkinson\u2019s disease model to assess disease progression and therapy efficiency","volume":"15","author":"Hughes","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2023.115258_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000440845","article-title":"Levodopa-induced motor and dopamine receptor changes in Caenorhabditis elegans overexpressing human alpha-synuclein","volume":"16","author":"Gupta","year":"2016","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.biopha.2023.115258_bib43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/2472555220958386","article-title":"Major improvements in robustness and efficiency during the screening of novel enzyme effectors by the 3-point kinetics assay","volume":"26","author":"Pinto","year":"2021","journal-title":"SLAS Discov."},{"key":"10.1016\/j.biopha.2023.115258_bib44","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1096\/fj.03-0770fje","article-title":"Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson\u2019s and Alzheimer\u2019s disease","volume":"18","author":"Li","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2023.115258_bib45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nchembio.1988","article-title":"An in vivo platform for identifying inhibitors of protein aggregation","volume":"12","author":"Saunders","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2023.115258_bib46","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.1063522","article-title":"Kinetic stabilization of the \u03b1-Synuclein protofibril by a dopamine-\u03b1-synuclein adduct","volume":"294","author":"Conway","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.115258_bib47","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/jnc.12686","article-title":"Protective and toxic roles of dopamine in Parkinson\u2019s disease","volume":"129","author":"Segura-Aguilar","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2023.115258_bib48","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/mds.27607","article-title":"The usual suspects, dopamine and alpha\u2010synuclein, conspire to cause neurodegeneration","volume":"34","author":"Mor","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2023.115258_bib49","doi-asserted-by":"crossref","first-page":"14941","DOI":"10.1074\/jbc.M109.080390","article-title":"Entacapone and tolcapone, two catechol o-methyltransferase inhibitors, block fibril formation of \u03b1-synuclein and \u03b2-amyloid and protect against amyloid-induced toxicity","volume":"285","author":"Di Giovanni","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.115258_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/14740338.4.1.69","article-title":"Tolcapone in Parkinson\u2019s disease: liver toxicity and clinical efficacy","volume":"4","author":"Borges","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.biopha.2023.115258_bib51","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of Parkinsonism \u2014 chronic treatment with L-Dopa","volume":"280","author":"Cotzias","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115258_bib52","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/mds.27216","article-title":"Levodopa: a new look at an old friend: a new look at Levodopa","volume":"33","author":"Olanow","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2023.115258_bib53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0165-0173(97)00048-9","article-title":"The emergence of the volume transmission concept","volume":"26","author":"Zoli","year":"1998","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.biopha.2023.115258_bib54","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00702-010-0454-z","article-title":"Postsynaptic nigrostriatal dopamine receptors and their role in movement regulation","volume":"117","author":"Korchounov","year":"2010","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.biopha.2023.115258_bib55","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1073\/pnas.1513619112","article-title":"Subsecond dopamine fluctuations in human striatum encode superposed error signals about actual and counterfactual reward","volume":"113","author":"Kishida","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2023.115258_bib56","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.25364","article-title":"Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts","volume":"84","author":"Espay","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2023.115258_bib57","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/brain\/aww228","article-title":"Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3","volume":"139","author":"Costa","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2023.115258_bib58","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3390\/biomedicines10020370","article-title":"Aripiprazole offsets mutant ATXN3-induced motor dysfunction by targeting dopamine D2 and serotonin 1A and 2A receptors in C. elegans","volume":"10","author":"Jalles","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2023.115258_bib59","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/jnnp.57.8.903","article-title":"The Sydney Multicentre Study of Parkinson\u2019s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa","volume":"57","author":"Hely","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2023.115258_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.569594","article-title":"Very-low-dose levodopa therapy for pediatric neurological disorders: a preliminary questionnaire in Japan","volume":"9","author":"Hoshino","year":"2021","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.biopha.2023.115258_bib61","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mds.26082","article-title":"Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics: levodopa pharmacokinetics and pharmacodynamics","volume":"30","author":"LeWitt","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2023.115258_bib62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pneurobio.2013.01.001","article-title":"Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7","volume":"104","author":"R\u00fcb","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.biopha.2023.115258_bib63","first-page":"994","article-title":"Decreased dopamine transporter binding in Machado-Joseph disease","volume":"41","author":"Yen","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2023.115258_bib64","first-page":"153","article-title":"Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers","volume":"43","author":"Yen","year":"2002","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2023.115258_bib65","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neulet.2011.09.006","article-title":"Transcranial sonography findings in spinocerebellar ataxia type 3 (Machado\u2013Joseph disease): a cross-sectional study","volume":"504","author":"Pedroso","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2023.115258_bib66","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archneur.1996.00550110120020","article-title":"Limits of clinical assessment in the accurate diagnosis of Machado-Joseph Disease","volume":"53","author":"Lopes-Cendes","year":"1996","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.biopha.2023.115258_bib67","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.parkreldis.2015.10.016","article-title":"Dystonia in Machado\u2013Joseph disease: clinical profile, therapy and anatomical basis","volume":"21","author":"Nunes","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.biopha.2023.115258_bib68","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.10322","article-title":"Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease","volume":"18","author":"Buhmann","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2023.115258_bib69","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1212\/WNL.0000000000007745","article-title":"Age at onset in genetic prion disease and the design of preventive clinical trials","volume":"93","author":"Minikel","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2023.115258_bib70","first-page":"54","article-title":"Correlation between CAG repeat length and clinical features in Machado-Joseph disease","volume":"57","author":"Maciel","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.biopha.2023.115258_bib71","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur. Heart J."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223010491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223010491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:14:35Z","timestamp":1777878875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223010491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":71,"alternative-id":["S0753332223010491"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115258","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.12.01.518659","asserted-by":"object"}]},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing of dopaminergic drugs to inhibit ataxin-3 aggregation","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115258"}}